Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The natural killer group 2D (NKG2D) is an activating receptor that expresses on the surface of various immune cells, including natural killer (NK) cells and certain T cells. NKG2D ligands (NKG2DL) are proteins that can bind to the NKG2D receptor. Under normal circumstances, these ligands are not expressed in significant amounts. However, NKG2DL can be upregulated under stress conditions such as viral infection or transformation of the cell to a cancerous state. Senescent cells often overexpress NKG2DL, thus making them visible to the immune system. When NKG2D receptors on NK or T cells bind to NKG2DL on senescent cells, it triggers an immune response leading these cells to release cytotoxic molecules that can kill the senescent cells. Through this mechanism, the immune system can eliminate potentially harmful senescent cells, a process important for tissue homeostasis and tumor surveillance.
Fig.1 Activation of NKG2D-NKG2DL related pathways.1
Senescent cells accumulate in aging bodies and contribute to many age-related pathologies, including cancers and degenerative diseases. These cells stop dividing, often in response to damage or stress, and secrete inflammatory molecules that can harm surrounding tissues. CAR-T therapy has expanded into the anti-aging field. NKG2D CAR-T cell therapy may represent a novel strategy for tackling senescent cells. The NKG2D CAR-T cells can recognize and destroy cells expressing NKG2D ligands, which are often found on tumor and senescent cells. This means that they could potentially be used to target and kill senescent cells in the treatment of aging and age-related diseases.
Fig.2 Selective elimination of NKG2DLs-expressing senescent cells by NKG2D-CAR T cells.2
At Creative Biolabs, we are proud to offer NKG2D-CAR T cell development services. Our dedicated team of scientists is experienced in designing and constructing CAR T cell research studies tailored to meet your requirements. These NKG2D-CAR T cells are equipped with a receptor called NKG2D as the antigen-binding domain which recognizes NKG2DL proteins that are overexpressed on the surface of senescent cells. When these modified T cells encounter a senescent cell, they bind to it and trigger a cascade of events that lead to cell death.
Besides, we offer high-quality CAR T cell services to assess the functionality and specificity of engineered T cells in vitro and in vivo. We use advanced techniques such as flow cytometry, cytotoxicity assays, cytokine release assays, as well as proliferation and apoptosis assays to ensure the highest quality of our NKG2D-CAR T cell products. Our in vivo services include validating the efficacy and safety of CAR T cells in relevant animal models. We perform in-depth antitumor activity assessment, and survival studies, and use cutting-edge imaging methods to verify the distribution, targeting effectiveness, and persistence of the therapeutic cells within the organism.
Please contact us for more details about our NKG2D-CAR T cell development services.
References
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
